Company’s 36-month beta value is -1.23.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CADL is 30.51M, and currently, short sellers hold a 8.66% ratio of that floaft. The average trading volume of CADL on February 19, 2025 was 4.03M shares.
CADL) stock’s latest price update
Candel Therapeutics Inc (NASDAQ: CADL)’s stock price has increased by 5.78 compared to its previous closing price of 9.52. However, the company has seen a 21.47% increase in its stock price over the last five trading sessions. proactiveinvestors.com reported 2025-01-13 that Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024. Updated overall survival data from phase 2a trials of its lead candidate CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) are expected in the first quarter of 2025.
CADL’s Market Performance
Candel Therapeutics Inc (CADL) has seen a 21.47% rise in stock performance for the week, with a 51.09% gain in the past month and a 134.19% surge in the past quarter. The volatility ratio for the week is 7.37%, and the volatility levels for the past 30 days are at 7.33% for CADL. The simple moving average for the last 20 days is 28.23% for CADL stock, with a simple moving average of 46.58% for the last 200 days.
Analysts’ Opinion of CADL
BofA Securities, on the other hand, stated in their research note that they expect to see CADL reach a price target of $15. The rating they have provided for CADL stocks is “Buy” according to the report published on February 07th, 2025.
H.C. Wainwright gave a rating of “Buy” to CADL, setting the target price at $11 in the report published on December 02nd of the previous year.
CADL Trading at 29.80% from the 50-Day Moving Average
After a stumble in the market that brought CADL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.03% of loss for the given period.
Volatility was left at 7.33%, however, over the last 30 days, the volatility rate increased by 7.37%, as shares surge +52.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +126.92% upper at present.
During the last 5 trading sessions, CADL rose by +21.26%, which changed the moving average for the period of 200-days by +25.97% in comparison to the 20-day moving average, which settled at $7.85. In addition, Candel Therapeutics Inc saw 16.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CADL starting from Barone Francesca, who sale 13,534 shares at the price of $7.22 back on Jan 15 ’25. After this action, Barone Francesca now owns 110,673 shares of Candel Therapeutics Inc, valued at $97,783 using the latest closing price.
Tyagarajan Seshu, the Chief Technology Officer of Candel Therapeutics Inc, sale 14,322 shares at $7.22 during a trade that took place back on Jan 15 ’25, which means that Tyagarajan Seshu is holding 96,790 shares at $103,476 based on the most recent closing price.
Stock Fundamentals for CADL
Current profitability levels for the company are sitting at:
- -20.02 for the present operating margin
- 0.54 for the gross margin
The net margin for Candel Therapeutics Inc stands at -29.39. The total capital return value is set at -5.69. Equity return is now at value -1344.47, with -145.85 for asset returns.
Based on Candel Therapeutics Inc (CADL), the company’s capital structure generated 20.92 points at debt to capital in total, while cash flow to debt ratio is standing at -1.79. The debt to equity ratio resting at -1.05. The interest coverage ratio of the stock is -14.98.
Currently, EBITDA for the company is -37.43 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 248.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
In a nutshell, Candel Therapeutics Inc (CADL) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
